Related Experiment Videos
Efficacy of fluvoxamine in severe depression
1Clinique Universitaire de Bruxelles, Hôpital Erasme, Service de Psychiatrie, Belgium.
Drugs
|January 1, 1992
Summary
Fluvoxamine effectively treats depression, particularly severe cases, compared to placebo over 4-6 weeks. High placebo response rates in some studies warrant further investigation into treatment efficacy.
Area of Science:
- Psychiatry and Clinical Pharmacology
- Neuroscience
- Pharmacological Research
Background:
- Fluvoxamine is an antidepressant medication.
- Comparative studies are essential for evaluating drug efficacy.
- Imipramine serves as an active reference compound in antidepressant trials.
Purpose of the Study:
- To assess the therapeutic efficacy of fluvoxamine in treating depression.
- To compare fluvoxamine's effectiveness against placebo and imipramine.
- To investigate the impact of depression severity on treatment response.
Main Methods:
- Conducting comparative double-blind placebo-controlled studies.
- Utilizing imipramine as an active reference.
- Treating patients for 4 to 6 weeks.
Main Results:
- Fluvoxamine demonstrated significant depression amelioration compared to placebo.
- Patients with severe depression showed a greater response rate to fluvoxamine.
- High placebo response rates were observed in some studies, with similar response rates to imipramine and placebo in certain instances.
Conclusions:
- Fluvoxamine is a therapeutically effective antidepressant, especially for severe depression.
- Observed high placebo response rates necessitate further research to clarify treatment effectiveness and methodological factors.